to be marketed as Cardura® XL.It is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It cardura doxazosin mesylate 1 mg cardura doxazosin mesylate 1 mg alpha-1 adrenergic receptor blocker cardura doxazosin mesylate 1 mg inhibits the binding inhibits.

searchDoxazosinSystematic (IUPAC) name[4-(4-amino-6,7-dimethoxy- quinazolin-2-yl) piperazin-1-yl]- (2,5-dioxabicyclo[4.4.0] deca-6,8,10-trien-4-yl) methanoneIdentifiersCAS number 74191-85-8ATC code C02CA04PubChem 3157DrugBank APRD00474Chemical dataFormula C23H25N5O5Mol. mass 451.475 g/molPharmacokinetic dataBioavailability 65%Protein binding 98%Metabolism cardura doxazosin mesylate 1 mg life 22 hoursExcretion ?Therapeutic considerationsPregnancy cat. ?Legal status ? Prescription cardura doxazosin mesylate 1 mg oralDoxazosin mesylate, a quinazoline compound sold by Pfizer under the brand names Cardura® and Carduran® , is an cardura doxazosin mesylate 1 mg blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as cardura doxazosin mesylate 1 mg XL.It is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On cardura doxazosin mesylate 1 mg 22, 2005, the US FDA approved a sustained release cardura doxazosin mesylate 1 mg of doxazosin, to be marketed cardura doxazosin mesylate 1 mg Cardura® XL.It is an alpha blocker used to treat high blood.

The primary cardura doxazosin mesylate 1 mg of this blockage is relaxed vascular smooth muscle tone (vasodilation), which decreases peripheral vascular.